Cytokine therapy restores antitumor responses of NK cells rendered anergic in MHC I-deficient tumors

Michele Ardolino; David H Raulet

doi:10.1080/2162402X.2014.1002725

Cytokine therapy restores antitumor responses of NK cells rendered anergic in MHC I-deficient tumors

Oncoimmunology. 2015 Jun 5;5(1):e1002725. doi: 10.1080/2162402X.2014.1002725. eCollection 2016.

Authors

Michele Ardolino¹, David H Raulet¹

Affiliation

¹ Department of Molecular and Cell Biology, and Cancer Research Laboratory; Division of Immunology and Pathogenesis; Department of Molecular and Cell Biology; University of California, Berkeley ; Berkeley, CA USA.

Abstract

Recent extraordinary advances in cancer immunotherapy rely primarily on marshaling T cell responses. Here we discuss how NK cell responses can be amplified. We find that MHC I-deficient tumors induce anergy of NK cells but that cytokine therapy restores NK cell activity and increases the survival of mice bearing MHC I-deficient tumors.

Keywords: NK cells; cancer immunotherapy; cytokines.

Publication types

Research Support, Non-U.S. Gov't

Grants and funding

R01 AI039642/AI/NIAID NIH HHS/United States